The mission of the Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (WRCE) is the creation of synergistic,.multifaceted research, strong infrastructure, and activities to develop vaccines, therapeutics, and diagnostics against natural and manmade emerging infectious disease threats by applying the best basic and translational science. Scientists from 22 institutions propose to conduct 15 major research projects and provide six supportive core activities. The WRCE is a unifying force in Texas, New Mexico, Oklahoma, Arkansas, and Louisiana for collaborative research on infectious diseases. The evaluation of the national RCE program revealed that the WRCE was the top performer in the number of new investigators in biodefense, number of projects, number of organisms studied, number of patents filed, and number of new projects supported by other funds that stemmed from RCE projects. Successful basic scientists with substantial expertise in Category A-C agents have truly embraced the unfamiliar goal of translational product-oriented research. The 15 major projects address four themes: development of therapeutic agents for RNA viruses, platforms for multiplexed diagnostics for Category A-C agents and emerging agents, vaccine development for arboviral and emerging viral diseases, and vaccine development for diseases caused by intracellular bacteria. The 15 projects are currently pursuing new specific aims;this is a result of the WRCE's strategy in the previous grant cycle to support developmental type grants to initiate next-stage projects, and an early competition for major projects one year before the completion of the cycle. This planning process allowed selection of the best, most relevant science and development of synergistic interactions within the themes. Attentive guidance by the administrative core's analysis of progress reports, site visits, regional meetings, workshops, and formal external product development consultations support research activities, along with monthly theme meetings to ensure the continued success of projects. Highly productive scientists utilize such regional sources as three national primate research centers, 19 institutions with BSL-3 laboratories, two institutions with BSL-4 laboratories, two vaccine development centers, two DOE national laboratories, 13 participating medical universities, three participating veterinary schools, and four institutions with aerobiology expertise to translate their outstanding scientific knowledge into program that delivers more than the sum of its parts.

Public Health Relevance

The Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research scientific program supports the national effort toward developing new drugs, diagnostics, and vaccines for infectious disease agents. The emergency response preparedness plan also ensures that facilities and subject matter expertise will be provided during a bioterror event or naturally occurring outbreak.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54AI057156-09
Application #
8247682
Study Section
Special Emphasis Panel (ZAI1-DDS-M (J2))
Program Officer
Schaefer, Michael R
Project Start
2003-09-04
Project End
2014-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
9
Fiscal Year
2012
Total Cost
$7,824,251
Indirect Cost
$1,040,000
Name
University of Texas Medical Br Galveston
Department
Pathology
Type
Schools of Medicine
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Navarro, Juan-Carlos; Giambalvo, Dileyvic; Hernandez, Rosa et al. (2016) Isolation of Madre de Dios Virus (Orthobunyavirus; Bunyaviridae), an Oropouche Virus Species Reassortant, from a Monkey in Venezuela. Am J Trop Med Hyg 95:328-38
Park, Arnold; Yun, Tatyana; Hill, Terence E et al. (2016) Optimized P2A for reporter gene insertion into Nipah virus results in efficient ribosomal skipping and wild-type lethality. J Gen Virol 97:839-43
Aghazadeh, Amirali; Lin, Adam Y; Sheikh, Mona A et al. (2016) Universal microbial diagnostics using random DNA probes. Sci Adv 2:e1600025
Inglis, Fiona M; Lee, Kim M; Chiu, Kevin B et al. (2016) Neuropathogenesis of Chikungunya infection: astrogliosis and innate immune activation. J Neurovirol 22:140-8
Hatcher, Christopher L; Mott, Tiffany M; Muruato, Laura A et al. (2016) Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders. Infect Immun 84:2345-54
Chen, Hui; Hagström, Anna E V; Kim, Jinsu et al. (2016) Flotation Immunoassay: Masking the Signal from Free Reporters in Sandwich Immunoassays. Sci Rep 6:24297
Crannell, Zachary Austin; Cabada, Miguel Mauricio; Castellanos-Gonzalez, Alejandro et al. (2015) Recombinase polymerase amplification-based assay to diagnose Giardia in stool samples. Am J Trop Med Hyg 92:583-7
Walker, David H; Dumler, J Stephen (2015) The role of CD8 T lymphocytes in rickettsial infections. Semin Immunopathol 37:289-99
Mott, Tiffany M; Vijayakumar, Sudhamathi; Sbrana, Elena et al. (2015) Characterization of the Burkholderia mallei tonB Mutant and Its Potential as a Backbone Strain for Vaccine Development. PLoS Negl Trop Dis 9:e0003863
Gregory, Anthony E; Judy, Barbara M; Qazi, Omar et al. (2015) A gold nanoparticle-linked glycoconjugate vaccine against Burkholderia mallei. Nanomedicine 11:447-56

Showing the most recent 10 out of 362 publications